Document is current

Article History

Received: 23 February 2023

Accepted: 12 July 2023

First Online: 17 August 2023

Competing interests

: A.V. declares employment by Caris Life Sciences and consults with the George Clinical, West Clinic; he sits on the advisory boards and steering committees of Bristol Myers Squibb, Genentech and Mirati Therapeutics. He has received research funding from SWOG, Stand Up 2 Cancer, Bristol Myers Squibb and American Association for Cancer Research. K.L.K. reports clinical trial funding through the institution from Merck. N.I.K. sits on the advisory board for Bristol Myers Squibb, Regeneron, Merck, Iovance Biotherapeutics, Genzyme, Novartis, Nektar, Castle Biosciences, Instil Bio and the National Comprehensive Cancer Network (via Pfizer); he is a member of the study steering committees of Bristol Myers Squibb, Nektar, Regeneron and Replimune; he is a member of the data safety monitoring boards of Astra-Zeneca and Incyte; he holds common stock stock in Bellicum Pharmaceuticals, Asensus Surgical and Amarin Corporation; and he has received research funding (to the institute) from Bristol Myers Squibb, Merck, Novartis, GSK, HUYA Bioscience International, Amgen, Regeneron, Celgene, Replimmune and Modulation Therapeutics. K.M.C. reports being a shareholder in Geneoscopy and has received consulting fees from Geneoscopy, PACT Pharma, Tango Therapeutics, Flagship Labs 81 and the Rare Cancer Research Foundation. P.S. received research funding, consulted for and served on the advisory board for Castle Biosciences. F.C. reports that his institution receives research funding for clinical trials. A portion of that funding comes from trials sponsored by Amgen and Replimune and helps cover her salary. J.A.S. reports consultation for Apixagen Consultation, Iovance and Necktor and up-to-date royalties. A.I. discloses research funding to her institution from Checkmate Pharmaceuticals, Dynavax Technologies, GSK/S. Cannon, Immunocore, Merck and Neon Therapeutics/S. Cannon. A.I.V. had an investigator-initiated study supported by Bristol Myers Squibb, but it closed 2 years ago and understands that it does not qualify as a competing interest. T.-G.T. reports institutional funding from Bristol Myears Squibb, Merck, Roche, Pfizer, Novartis, Regeneron and Astra-Zeneca. B.C. reports clinical trial support paid to his institution from SWOG, Bristol Myers Squibb, Macrogenics, Merck, Karyopharm, Infinity, Advenchen, Idera, Xencor, Compugen, Iovance, PACT Pharma, RAPT Therapeutics, Immunocore, IDEAYA, Ascentage, Novartis, Atreca, Replimmune, Instil Bio, Adagene, TriSalus and Xilio; he reports payment for lectures for Sanofi Genzyme and sits on the advisory boards of Instil Bio, Nektar, Delcath, Novartis, Genentech, IDEAYA, OncoSec, Iovance and Deciphera. Y.C. reports research funding from BMS RELATIVITY-098 to his institution, personal financial interest in Bristol Myers Squibb as speaker on melanoma and is a member of the advisory board; he has spoken about melanoma on behalf of Pfizer. D.B.J. has served on the advisory boards or as a consultant for Bristol Myears Squibb, Catalyst Biopharma, Iovance, Jansen, Mallinckrodt, Merck, Mosaic ImmunoEngineering, Novartis, Oncosec, Pfizer, Targovax and Teiko, and has received research funding from Bristol Myears Squibb and Incyte. Z.E. reports serving on the advisory boards of Array BioPharma, Pfizer, OncoSec, Regeneron, Genentech, Novartis and Natera; she has received research funding from Novartis, Pfizer and Boehringer Ingelheim. S.C. reports serving on the advisory boards of Bristol Myers Squibb, Novartis, Pfizer and Regeneron. S.H-L. reports consulting for Amgen, Genmab, Xencor, Regeneron, Nektar, Astellas, Bristol Myers Squibb and Merck; she reports support from Amgen and Merck, and has undertaken contracted research for Pfizer, Plexxikon, Genentech, Neon Therapeutics, Nektar, Astellas, F Star, Xencor, Merck, Vedanta, Kite Pharma, Boehringer Ingelheim, OncoC4, Dragonfly, Bristol Myers Squibb and BioAlta. S.P.P. reports the following relevant competing interests: clinical trial support to her institution from Bristol Myers Squibb; advisory board membership of Cardinal Health, Castle Biosciences and Delcath; serving as a consultant for Foghorn Therapeutics (clinical trial support to her institution); providing clinical trial support for Ideaya (via her institution); sitting on the data safety monitoring board of Immunocore; sitting on the advisory board of Immatics; providing clinical trial support via her institution to InxMed, Lyvgen Biopharma and Novartis; serving as consultant on the advisory board of Pfizer; providing clinical trial support to Provectus Biopharmaceuticals; providing clinical trial support via her institution to Reata Pharmaceuticals and sitting on the data safety monitoring board; she has sat on the advisory board of Replimmune and the scientific advisory board of TriSalus Life Sciences; and she has provided clinical trial support (via her institution) to Seagen and Syntrix Bio, and has consulted for Advance Knowledge in Healthcare. K.F.G. is an employee and stockholder of Merck Sharp & Dohme, a subsidiary of Merck & Co. A.R. has received honoraria from consulting with Amgen, Bristol Myers Squibb and Merck; is or has been a member of the scientific advisory board and holds stock in Advaxis, Appia, Apricity, Arcus, Compugen, CytomX, Highlight, ImaginAb, ImmPact, ImmuneSensor, Inspirna, Isoplexis, Kite-Gilead, Lutris, MapKure, Merus, PACT, Pluto, RAPT Therapeutics, Synthekine and Tango; and has received research funding from Agilent and from Bristol Myers Squibb through SU2C, and patent royalties from Arsenal Bio. J.M., L.F.K., D.C.P., K.M., C.L.B., C.A.D., E.M., C.R.G., I.B.C., A.V-C., I.P.G., E.S., S.L.B. and M.C.W. declare no competing interests.